Drug intelligence / Profile preview

ALKS 7119

Development stage: Unknown
Lead developer: Alkermes
Modality: Small Molecules
Administration: Oral

Overview

ALKS 7119 is an investigational, orally bioavailable small molecule developed by Alkermes for the treatment of agitation in Alzheimer's disease, major depressive disorder (MDD), and other central nervous system (CNS) disorders. It utilizes a multivalent mechanism of action, acting as an N-methyl-D-aspartate (NMDA) receptor antagonist and a serotonin reuptake transporter (SERT) inhibitor. This dual-action profile is intended to address the complex neurobiology of neuropsychiatric symptoms. Clinical development commenced in 2016 with Phase 1 trials in healthy volunteers to evaluate safety, tolerability, and pharmacodynamic effects.

Targets

SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)ADRA1A (α1A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1B (α1B)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ALKS 7119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALKS 7119.

Explore the full profile